ArticleJournal of family medicine and primary care2025
Access to essential medicines in aspirational districts of India; A multi-site cross sectional study.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gaps in access and trust: essential medicine availability, affordability, and barriers to generic medicine use.Public health action · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Inequitable access to essential medicines (EMs) is a big challenge for optimal delivery of health care in a country like India. Baseline data is essential to develop effective public health policy to facilitate equitable access to EMs. The primary purpose of this research was to investigate the price, availability, and affordability EMs in the aspirational districts of Odisha using WHO/HAI methodology. Materials and Methods: The study was carried out in 25 public health facilities and 25 private pharmacies. Data on availability and price of EMs was collected from both public health facilities and private pharmacies. Prices were compared to an international reference price (expressed as median price ratio-MPR). Treatment affordability also was calculated for surveyed EMs. Results: The overall percent availability of lowest price generics (LPGs) was 62% in the public health facilities and 58% in private pharmacies. The procurement price of surveyed medicines for public health facilities was 0.28 (IQR, 0.17, 0.50) times of IRP, whereas price charged to patients for the same in retail pharmacies was 1.34 (IQR, 0.71 to 2.4) of IRP. Most of the surveyed medicines in private pharmacies required for acute conditions were affordable except amoxicillin/clavulanic acid 625 mg tablet that was slightly unaffordable, with a single course of treatment costing up to 1.21 days of wages. Conclusion: This study revealed that overall availability of surveyed EMs in both public sector facilities and private pharmacies was optimal. Both procurement prices and prices charged to patients of surveyed medicines were reasonable in comparison to IRP. Availability of EMs has improved and many medicines are now affordable. These data have significant policy implications that could help in amending policies to further increase the access to EMs for patients residing in remote areas of the country.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.